Self-emulsifying drug delivery systems (SEDDS) are modern forms for drug agent delivery with improved biopharmaceutical characteristics. By their formation mechanism they belong to the group of in situ systems - forms formed at the application site, under the influence of specific physiological or pathological factors. Dermatological SEDDS for external use that form an emulsion at the absorption site upon contact with water are characterized by a number of advantages, both in terms of use and technology. Moisture-sensitive SEDDS are compositions of oil, surfactant, emollients and co-surfactants. Emulsification occurs with minimal mechanical action, and the emulsion formed provides effective transdermal absorption of the active ingredients, soothing, moisturizing, and protective effects on the skin. All these advantages can be effectively applied in local symptomatic treatment of atopic dermatitis. Topical SEDDS are currently known to be developed for the treatment of melanoma, viral and fungal diseases, protection against ultraviolet radiation. Atopic dermatitis (AD) is a chronic dermatological disease accompanied by itching, burning, dry and flaky skin, reduced protective function of the epidermis, susceptibility to fungal and bacterial infections. Using alkaline skin care products for patients with AD negatively affects the pH of the skin and affects it accordingly. In addition, the using of soaps causes thinning of the skin in both normal and atopic skin, which can aggravate the course of the disease. Therefore, the use of moisture-activated SEDDS in the complex external treatment of AD is reasonable both as agents for daily skin care, maintenance of its basic functions, and as drugs for transdermal delivery of active ingredients.